Condition
Metastatic or Locally Advanced Unresectable Solid Tumors
Total Trials
4
Recruiting
0
Active
2
Completed
0
Key Insights
Highlights
No notable highlights available yet
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 100/100
Termination Rate
50.0%
2 terminated out of 4 trials
Success Rate
0.0%
-86.5% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
2 of 0 completed with results
Key Signals
2 with results0
Data Visualizations
Phase Distribution
4Total
P 1 (4)
Trial Status
Active Not Recruiting2
Terminated2
Clinical Trials (4)
Showing 4 of 4 trials
NCT04170153Phase 1Active Not RecruitingPrimary
Tuvusertib (M1774) in Participants With Metastatic or Locally Advanced Unresectable Solid Tumors (DDRiver Solid Tumors 301)
NCT05198349Phase 1TerminatedPrimary
First in Human Study of M1069 in Advanced Solid Tumors
NCT05396833Phase 1Active Not RecruitingPrimary
Study of Tuvusertib (M1774) in Combination With DNA Damage Response Inhibitor or Immune Checkpoint Inhibitor (DDRiver Solid Tumors 320)
NCT03306420Phase 1TerminatedPrimary
First-in-Human Study of MS201408-0005A as Single Agent and in Combinations
Showing all 4 trials